Abstract
The main challenge of cancer treatment is multidrug resistance during chemotherapy. Cancer cell can evade cell death during every round of orthodox chemotherapy drugs, consequently being resistant after several rounds of standard drug treatment. One of the regimens to address this multidrug resistance problem is by drug combination. However, synthetic drugs always have problems of strong side effects and toxicity. Natural compounds deriving from traditional Chinese medicine are known to have low toxicity and genuine promising effects in reversing multidrug resistance, either induced by orthodox chemotherapeutic or targeted therapy drugs. Numerous mechanisms including suppression of drug efflux, detoxifying systems, DNA repair systems, and anti-apoptosis pathways were responsible for such process. A range of natural compounds functioned on the suppression of apoptosis are widely reported, which include flavonoids, terpenoids, alkaloids, quinones, xanthones, saponins and polysaccharides. Here, this review summarized comprehensive data from in vitro and in vivo studies to elucidate the functional roles of natural compounds in reversing multidrug resistance during cancer therapy.
Keywords: Traditional Chinese medicine, multi-drug resistance, phytomedicine, chemotherapy, natural compounds, combination.
Current Medicinal Chemistry
Title:Cancer Treatment by Using Traditional Chinese Medicine: Probing Active Compounds in Anti-multidrug Resistance During Drug Therapy
Volume: 25 Issue: 38
Author(s): Jian-Shu Lou, Ping Yao and Karl W.K. Tsim*
Affiliation:
- Division of Life Science, Center for Chinese Medicine, The Hong Kong University of Science and Technology, Hong Kong,China
Keywords: Traditional Chinese medicine, multi-drug resistance, phytomedicine, chemotherapy, natural compounds, combination.
Abstract: The main challenge of cancer treatment is multidrug resistance during chemotherapy. Cancer cell can evade cell death during every round of orthodox chemotherapy drugs, consequently being resistant after several rounds of standard drug treatment. One of the regimens to address this multidrug resistance problem is by drug combination. However, synthetic drugs always have problems of strong side effects and toxicity. Natural compounds deriving from traditional Chinese medicine are known to have low toxicity and genuine promising effects in reversing multidrug resistance, either induced by orthodox chemotherapeutic or targeted therapy drugs. Numerous mechanisms including suppression of drug efflux, detoxifying systems, DNA repair systems, and anti-apoptosis pathways were responsible for such process. A range of natural compounds functioned on the suppression of apoptosis are widely reported, which include flavonoids, terpenoids, alkaloids, quinones, xanthones, saponins and polysaccharides. Here, this review summarized comprehensive data from in vitro and in vivo studies to elucidate the functional roles of natural compounds in reversing multidrug resistance during cancer therapy.
Export Options
About this article
Cite this article as:
Lou Jian-Shu , Yao Ping and Tsim W.K. Karl *, Cancer Treatment by Using Traditional Chinese Medicine: Probing Active Compounds in Anti-multidrug Resistance During Drug Therapy, Current Medicinal Chemistry 2018; 25 (38) . https://dx.doi.org/10.2174/0929867324666170920161922
DOI https://dx.doi.org/10.2174/0929867324666170920161922 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genome-Wide Analysis of Low Dose Bisphenol-A (BPA) Exposure in Human Prostate Cells
Current Genomics Micelle-based Systems for Pulmonary Drug Delivery and Targeting
Drug Delivery Letters Meet Our Editorial Board Member
Mini-Reviews in Medicinal Chemistry Recent Progress in Structure Activity Relationship and Mechanistic Studies of Taxol Analogues
Mini-Reviews in Medicinal Chemistry PET Molecular Imaging of Hypoxia in Ischemic Stroke: An Update
Current Vascular Pharmacology HCV-Related Rheumatic Manifestations and Therapeutic Strategies
Current Drug Targets The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry MGBG in Combined Anticancer Chemotherapy
Letters in Drug Design & Discovery Severe Hypoglycemia Due to Possible Interaction Between Glibenclamide and Sorafenib in a Patient with Hepatocellular Carcinoma
Current Drug Safety A Comprehensive Review on Combretastatin Analogues as Tubulin Binding Agents
Current Organic Chemistry Therapeutic Proteins in Tumors and Targeted Therapeutic Agents for Cancer Patients
Protein & Peptide Letters Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations
Current Drug Targets Effects of Amine Oxidases in Allergic and Histamine-Mediated Conditions
Recent Patents on Inflammation & Allergy Drug Discovery Aptamers Against Cell Surface Receptors: Selection, Modification and Application
Current Medicinal Chemistry The Role of Amitriptyline in the Management of Non-small Cell Lung Cancer
Current Cancer Therapy Reviews The Design of Clinical Trials for New Molecularly Targeted Compounds: Progress and New Initiatives
Current Pharmaceutical Design Novel Folate-Hydroxamate Based Antimetabolites: Synthesis and Biological Evaluation
Medicinal Chemistry Targeting Endothelial Progenitor Cells in Cancer as a Novel Biomarker and Anti-Angiogenic Therapy
Current Stem Cell Research & Therapy Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design In Vitro and In Vivo Evaluation of [99mTc(CO)3]-Radiolabeled ErbB-2-Targeting Peptides for Breast Carcinoma Imaging
Current Radiopharmaceuticals